



Antihyperglycemic, Endothelial protection and Toxicity study of Basil Leaves Extract on Diabetic Rats

Sry Suryani Widjaja^{1*}, Rusdiana Rusdiana¹, Maya Savira², Rina Amelia³

¹Department of Biochemistry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia; ²Department of Physiology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia; ³Department of Community Medicine and Public Health, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

Abstract

Edited by: Sinisa Stojanoski

Citation: Widjaja SS, Rusdiana R, Savira M, Amelia R. Antihyperglycemic, Endothelial protection and Toxicity study of Basil Leaves Extract on Diabetic Rats. Open Access Maced J Med Sci. 2021 Jul 27; 9(A):589-594. <https://doi.org/10.3889/oamjms.2021.6520>

Keywords: Antihyperglycemic; Basil leaves; Blood glucose; Diabetic rats; Endothelial dysfunction; Toxicity

*Correspondence: Sry Suryani Widjaja, Ji. Joserizal No. 33E/51 Medan 20214 Indonesia.

E-mail: srysuryani@gmail.com

Received: 24-May-2021

Revision: 30-Jun-2021

Accepted: 07-Jul-2021

Copyright: © 2021 Sry Suryani Widjaja, Rusdiana Rusdiana, Maya Savira, Rina Amelia

Funding: This study was supported by the Ministry of Research and Technology and Higher Education Republic Indonesia, under research grant DRPM

Competing Interests: The authors have declared that no competing interests exist

Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)

BACKGROUND: Diabetes Mellitus (DM) remains a serious debilitating global health problem in low- and middle-income countries with rising incidence of DM-related complications due to ineffective Diabetic control. Herbs of the Ocimum family, especially *Ocimum basilicum* or basil leaves, have been investigated for their antihyperglycemic properties.

AIM: This study aimed to demonstrate the antihyperglycemic effect, endothelial protection, and toxicity of basil leaves on Diabetes-induced Wistar rats *in vivo*.

METHODS: Streptozosin injections were used to induced diabetes in male Wistar rats. Basil leaves extracts 100, 300, and 1000 mg/kg BW were introduced to diabetic rats. Blood glucose levels (BGL), soluble Advanced Glycation End, tumor necrosis factor- α , interleukin (IL)-6, IL-2 were measured using enzyme-linked immunosorbent assay. Kidney and liver functions together with the histopathology reports were reported for acute, subacute, and chronic toxicity studies.

RESULTS: Basil leaves exposure significantly lowers BGL ($p < 0.00$), but yielded no statistically significant difference between extract doses. Hemostatic parameters showed significantly reduced endothelial dysfunction markers for all doses compared to control. Toxicity study yielded no differences between control and any doses of basil leaves in all acute, subacute, and chronic toxicity studies. Histopathological findings exhibited no evidence of tissue damage on the liver, kidney, heart, pancreas, lung, and lymph tissues in either control or experiment rats.

CONCLUSIONS: Basil leaves exposure were positively associated with lower glucose level, lower endothelial activation markers on Diabetic rats. The toxicity and histopathological results of the extract are on par with control.

Introduction

Diabetes Mellitus (DM) remains one of the major contributors of preventable chronic disease with an alarming increase in incidence around the world within the past few decades [1], [2]. Type 2 DM (T2DM) compose 90% of DM cases in adults, imposing a substantial burden, especially in low-and middle-income countries [2], [3], [4]. The underlying key events for the development of T2DM are chronic hyperglycemia and insulin resistance [5]. There is evidence of endothelial dysfunction, macro and microvascular complications that associated with high mortality and morbidity of T2DM patients [6]. Endothelial dysfunction and hyperglycemia heightened vascular damage including the production of advanced glycation end (AGEs) products seen as alteration of Von Willebrand factor (vWF) as indication for endothelial function in diabetic microangiopathy [6], [7], [8]. The recommendation for T2DM management focus on achieving long-term good metabolic control through the improvement of

lifestyle and pharmacological intervention, which can be seen from both macrovascular and microvascular complication endpoints [9], [10].

Dealing with diabetes and its complications requires very high patient compliance as the gold standard of treatment is the combination of diet, exercise, and medicine [11]. Standard drugs to control blood sugar levels and their complications have been circulating, but morbidity and mortality rates are still high, arguably, due to noncompliance with medication or fear of consuming drugs in the long term [12], [13]. Indonesia, particularly, with approximately 14 million T2DM patients, the fifth largest in the world, has been finding the importance of alternative treatments which are found abundant in herbal alternatives [14], [15].

Basil or *Ocimum basilicum* is a culinary herb of the Ocimum family or known as mints, abundantly found in Asia. The anti-diabetic properties have only been investigated in a few *in vitro* studies albeit showing a potential of lowering blood glucose level (BGL) through inhibition of the carbohydrate metabolizing enzyme, namely, amylase and glucosidase [16], [17], [18], [19].

Indonesia's archipelago and plethora of diverse medicinal plants have pioneered various studies on traditional medicines, including the usage of readily available basil leaves [20], [21], [22], [23]. Hence, it is imperative to further investigate basil leaves efficacy in the study using rats models.

Methods

This study was done after getting approved from the Health Research Ethical Committee Medical faculty of Universitas Sumatera Utara/H Adam malik General hospital number: 450/TGL/KEPK FK-USU-RSUPHAM/2018.

Preparation of basil extract

Basil extract was made using macerated dried *Ocimum sanctum*. The ground fine powder was extracted using 96% ethanol solution. The ethanol extract of basil leaves went through standardization using azeotropic distillation, gravimetry, and chromatography to determine water content, water solubility, and ethanol extract content, total ash content, acid insoluble content, as well as chromatogram profile. Afterward, suspension of each basil extract was made by mixing specific concentrations with carboxymethyl cellulose (CMC-Na) 2.0% solution.

Preparation of experimental animals, induction of diabetes, and introduction of extract

Male white Wistar rats of 180–200 g weight were prepared for two weeks to adapt to their surroundings, exposed to alternate 12 h of light and dark. Diabetes was induced by Streptozosin (STZ) injection. The STZ solution was prepared by dissolving STZ in a 50 mmol/L citrate buffer solution.

Wistar rats were fasted for approximately 18 hours, body weight (BW) weighed, and fasting blood sugar levels measured using the GlucoDr tool to obtain baseline data. STZ solution in citrate buffer 55 mg/kg BW was given through intraperitoneal injection. Rats blood sugar levels were measured on the 3rd and 7th days. On the 7th day, rats with BGLs higher than 250 mg/dl were grouped into tested group. Rats with blood sugar levels lower than 250 mg/dl were induced again. If on the 3rd day the BGL of the test animal is more than 250 mg/dl, then the rats would be grouped into treatment group.

Suspension of the test material (Basil extract) was administered orally and BGLs were measured on the 3rd, 7th, and 10th day after STZ induction. Each treatment group will be given basil extract dosage of 100, 300, 1000 mg/kgBW, respectively.

Antihyperglycemic effect of the basil extract

To evaluate the antihyperglycemic effect of basil extract, a total of 25 rats weigh 180–200 g were divided into five groups, which consist of three treatment groups of dosage (n = 5) of 100, 300, and 1000 mg, negative control group (normal rats), and positive control (diabetic rats without treatment). BGL was measured at days 0, 3, and 7 after STZ induction. Basil extract treatment started on day 7. The follow-up measurements of blood glucose was conducted at day 0, 3, 6, 9, 12, and 14 after treatment.

AGE, tumor necrosis factor (TNF)- α , vWF level assessment in rats

The values of the soluble AGE, TNF- α , interleukin (IL)-6, IL-2 were determined using a kit obtained from Fine Test and performed using the enzyme-linked immunosorbent assay method.

Toxicity study

A total of 50 rats induced with 50 mg/kg BW STZ solution underwent acute, subacute, and chronic toxicity study. Acute toxicity study utilizes lethal dose of 1500, 3000, and 5000 mg, subacute and chronic toxicity study at 100, 300, and 1000 mg. Evaluation of toxicity study comprised of BGL, liver function tests (Serum glutamic oxaloacetic transaminase [SGOT], serum glutamic pyruvic transaminase [SGPT], Alkaline Phosphatase, Gamma GT), kidney function tests (Urea and Creatinine), and endothelial activation (vWF and prothrombin fragment F1+2) of the STZ-induced rats.

Further, histopathological examination was conducted to evaluate toxicity through assessment of necrosis of liver cells, kidney cells, pancreas, heart, lung, brain parenchymal cells with H and E staining.

Statistical analysis

Statistical analysis was done on PRISM GraphPad version 8 and Statistical Package for Social Sciences. One-way analysis of variance and *Post-hoc* Tamhane test was done. The aqua dest control group was compared with the diabetic group. Data were expressed as mean \pm Standard deviation. The results were rationally analyzed and $p < 0.05$ was considered statistically significant.

Results

Baseline data of rats

To obtain baseline value, twenty-five male Wistar rats were selected, with average weight of 184.7 ± 13.6 g and average BGL 78.8 ± 9.0 mg/dL.

Effect on BGL

There was a consistent reduction on the average BGL after being given 100 mg/kg BW basil extract from 423 mg/dL on day 0, to day 3, 6, 9, 12, and 14, respectively, at 384 mg/dl, 268 mg dl, 189 mg/dl, 126 mg/dl, and 102 mg/dl. Similar reduction was found after 300 mg/kg BW basil extract administration, starting from 487 on day 0, 401.6 mg/dL at day 3 to 283 mg/dl on day 6, 214 on day 0, 137 mg/dL on day 12, and 93.3 mg/dL on day 14 [Figure 1].




Figure 1: Comparison of antihyperglycemic effect between dose 100 mg/kgBW, 300 mg/kgBW, and 1000 mg/kg BW

Overall, the highest reduction of BGL was achieved with Basil extract 1000 mg/kg BW at 83.75% followed by dosage 300 mg/kg BW at 80.34%, and finally the least dosage 100 mg/kg BW at 78.43%. In addition, control group did not complete the 14 days test, 80% of control sample died before day 14. Statistically, through the one-way ANOVA *Post hoc* Tamhane test, the reduction of BGL showed significant difference ($p < 0.00$) compared to control. However, the end result of BGL between dosage groups at day 14 did not yield statistically significant difference.

Results of Hemostatic Parameters Assessment in Rats

A total of 18 male Wistar rats were tested for changes in inflammatory and endothelial activation markers such as AGE, TNF- α , and vWF levels. We found no statistically significant difference of AGE level between normal control and basil leaves extract on all three dosages of 100 mg ($p = 0,12$), 200 mg ($p = 0,33$), and 400 mg ($p = 0,26$). On the other hand, basil leaves extract showed significant reduction of endothelial

activation shown by WF and TNF- α reduction compared to control.

Table 1: Blood chemistry markers on acute toxicity study obtained after lethal dose of basil extract

| Parameter | SGOT (IU/L) | SGPT (IU/L) | Alkaline Phosphatase (IU/L) | Gamma GT (U/L) | Urea (mg/dL) | Creatinine (mg/dL) |
|---------------|-------------|-------------|-----------------------------|----------------|--------------|--------------------|
| Control | 100 | 33 | 371 | 3.6 | 57.3 | 0.46 |
| Basil 1500 mg | 142 | 41 | 510 | 16 | 110 | 0.40 |
| Basil 3000 mg | 93 | 30 | 566 | 11 | 77 | 0.30 |
| Basil 5000 mg | 110 | 37 | 686 | 13 | 97 | 0.43 |

SGOT: Serum glutamic oxaloacetic transaminase, SGPT: Serum glutamic pyruvic transaminase.

Toxicity study

Effects on biochemical parameters

The acute toxicity study conducted did not show any morbidity or mortality, behavioral changes, or other symptoms. The blood chemistry markers on three dosages were within normal limits albeit slight elevation in SGPT, alkaline phosphatase, Gamma GT, and Urea levels, however, there was no statistically significant difference compared to control [Table 1]. The biochemical reference range for SGOT is 44-147 IU/L, SGPT 10-40 IU/L, ALP 50-150 IU/L, Gamma GT 1-5.3 U/L, urea 15-45 mg/dL, and creatinine 0.2-0.8 mg/dL [24], [25], [26], [27].

Table 2: Blood chemistry markers on subacute toxicity study

| Parameter | SGOT (IU/L) | SGPT (IU/L) | Alkaline Phosphatase (IU/L) | Gamma GT (U/L) | Urea (mg/dL) | Creatinine (mg/dL) |
|---------------|-------------|-------------|-----------------------------|----------------|--------------|--------------------|
| Control | 24 | 140 | 275 | 25 | 41 | 0.37 |
| Basil 100 mg | 69 | 165 | 255 | 30 | 53 | 0.43 |
| Basil 300 mg | 66 | 183 | 300 | 28 | 86 | 0.38 |
| Basil 1000 mg | 35 | 102 | 280 | 13 | 40 | 0.51 |

SGOT: Serum glutamic oxaloacetic transaminase, SGPT: Serum glutamic pyruvic transaminase.

As for the subacute toxicity study, throughout the period, there were no observed changes, symptoms, or behavioral and neurological alterations. There is no morbidity or mortality in all rate samples. The differences within and between groups are not significant [Table 2].

Table 3: Blood chemistry markers on chronic toxicity study

| Parameter | SGOT (IU/L) | SGPT (IU/L) | Alkaline Phosphatase (IU/L) | Gamma GT (U/L) | Urea (mg/dL) | Creatinine (mg/dL) |
|---------------|-------------|-------------|-----------------------------|----------------|--------------|--------------------|
| Control | 148.32 | 35 | 368 | 21.55 | 25.06 | 0.32 |
| Basil 100 mg | 88.99 | 35.66 | 377 | 11.8 | 30 | 0.43 |
| Basil 300 mg | 138.99 | 47.32 | 394 | 16.22 | 28.5 | 0.35 |
| Basil 1000 mg | 70.33 | 32.66 | 302 | 13.8 | 49.2 | 0.4 |

SGOT: Serum glutamic oxaloacetic transaminase, SGPT: Serum glutamic pyruvic transaminase.

Chronic toxicity study of basil leaves extracts effect on the treatment batch yields no changes in morbidity and mortality. There were inconsistent variations and increases of liver and kidney function tests results between dosages, however, the treatment groups showed no statistical differences compared to control group [Table 3].

Despite showing elevated numbers of alkaline phosphatase, and gamma GT, evaluation of blood chemistry markers of liver damage (SGOT, SGPT, Alkaline phosphatase, and gamma GT), markers of kidney damage (urea and creatinine) did not show significant differences between treatment group and control as well as within group.

Histopathological findings

Histopathological assessment on sections of the liver, kidney, heart, pancreas, lung, and lymph using light microscopy to assess the effect of basil leaves extract in STZ-induced diabetic tissues. Pathologically, all organ sections in all dosage groups did not show anatomical abnormalities administration compared to control group [Figure 2].

Liver cells showed normal and uniform arrangements of hepatocytes. Neither hepatocytes destruction nor congested hepatic inflammation was seen. In regards to lymph biopsy, there is no congestion or necrosis indicative of lymph damage. In all treatment and control groups, the renal tissue showed normal glomeruli, the epithelial lining of Bowman's capsule and mesangial cells, and no necrotic tissue found. The tubules were preserved well with normal columnar epithelial cells. Normal lung biopsy was obtained, the alveolar sac was not clearly seen. There is no foamy macrophage seen despite increase of infiltrate in the rat lung tissue. The pancreas was found normal, there was no evident of necrosis, degranulation, or shrinkage particularly in Langerhans Islet.

Discussion

Basil leaves is one of the numerous medicinal herbs recommended for Diabetes treatment. Previously, basil extract was found to decrease the classic Diabetes symptoms, namely, polydipsia, polyphagia, and polyuria in 30 T2DM patients with consumption of 2 g basil leaf powder for 3 months daily [28]. In the present study, the

effects, dosage, and toxicity of the basil leaves extract were evaluated in concordance to its anti-inflammatory properties.

Basil leaves, herbs from the *Ocimum* family have been proposed to possess antihyperglycemic properties in multiple studies [16], [17], [20], [29], [30], [31]. This study found significant blood glucose -lowering effect and endothelial protection of basil leaves. The findings are consistent with our previous study which also elucidates that basil leaves extract effectivity to reduce blood glucose was on par with Metformin 50 mg/kg BW control group [18].

Insulin-secretory effect of the *Ocimum* family was elucidated by Hannan *et al.*, as the extract enhances effects of insulin secretion from the pancreas, isolated islets, and modulation of intracellular calcium [30]. Basil leaves also shown to possess insulinotropic effect through the enhancement of physiological pathways on pancreatic beta-cells [20]. Thus, increasing plasma insulin and decreasing BGL in rats with type 2 diabetes [30].

In regard to biochemical markers, there is still lack of in-depth studies on the toxicity effect and biochemical profile of basil leaves. One attempt, by Huq *et al.*, in a basil-based tea, found that in addition to antidiabetic effect, there are no harmful effects on the liver by evaluation of SGPT [32], [33]. The anti-inflammatory effect of *Ocimum sanctum* was lacking as well. However, *Ocimum tenuiflorum* has been researched to possess pharmacological activities involving reduction of lipid peroxidation, increasing uptake of radical scavenging activity, and stimulation of antioxidant enzymes [33], [34].

Through histopathological biopsy, this study found normal results in the liver, kidney, lymph, lung,




Figure 2: Comparison of microscopic representation of histological sections in toxicity study. (a) Liver (b) Lymph (c) Kidney (d) Lung (e) Pancreas

and pancreas which are in concordance with the biochemical markers from blood tests. SGOT and SGPT were slightly increased but none of which showed significance difference compared to their control sample counterparts. In addition, all of the Wistar rats results of SGPT were increased. It is known that SGOT is the least specific of the two because SGOT was not only produced by the liver but also by the heart. On the other hand, SGPT directly reflects liver damage as it is directly produced by liver cells. Therefore, SGPT is the more reliable marker along with liver enzymes such as alkaline phosphatase [35], [36]. The increase in SGPT, ALP, and Gamma GT might indicate liver damage, however, it is debunked as even the normal Wistar rats possess similar levels of SGPT, ALP, and Gamma GT.

Conclusions

This study confirmed the antihyperglycemic and antiinflammatory effects of basil leaves (*Ocimum sanctum*), as well as safety in acute, subacute, and chronic setting. This study will be the pioneer to further unravel the potential of basil leaves extract for Diabetes treatment. In the future, more work needs to be directed in achieving characterization of active components and human trials to be further formulated into novel antidiabetic agents.

References

- Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol.* 2018;14(2):88-98. <https://doi.org/10.1038/nrendo.2017.151>
PMid:29219149
- Magliano DJ, Islam RM, Barr EL, Gregg EW, Pavkov ME, Harding JL, et al. Trends in incidence of total or Type 2 diabetes: Systematic review. *BMJ.* 2019;366:l5003. <https://doi.org/10.1136/bmj.l5003>
PMid:31511236
- Afroz A, Alramadan MJ, Hossain MN, Romero L, Alam K, Magliano DJ, et al. Cost-of-illness of Type 2 diabetes mellitus in low and lower-middle income countries: A systematic review. *BMC Health Serv Res.* 2018;18(1):972. <https://doi.org/10.1186/s12913-018-3772-8>
PMid:30558591
- Manne-Goehler J, Geldsetzer P, Agoudavi K, Andall-Brereton G, Aryal KK, Bicaba BW, et al. Health system performance for people with diabetes in 28 low-and middle-income countries: A cross-sectional study of nationally representative surveys. *PLoS Med.* 2019;16(3):e1002751. <https://doi.org/10.1371/journal.pmed.1002751>
PMid:30822339
- Schwartz SS, Epstein S, Corkey BE, Grant SF, Gavin JR, Aguilar RB. The time is right for a new classification system for diabetes: Rationale and implications of the β -cell-centric classification schema. *Diabetes Care.* 2016;39(2):179-86. <https://doi.org/10.2337/dci16-0011>
PMid:26798148
- Chawla A, Chawla R, Jaggi S. Microvascular and macrovascular complications in diabetes mellitus: Distinct or continuum? *Indian J Endocrinol Metab.* 2016;20(4):546-51. <https://doi.org/10.4103/2230-8210.183480>
PMid:27366724
- Mahdi A, Jiao T, Yang J, Kövamees O, Alvarsson M, von Heijne M, et al. The effect of glycemic control on endothelial and cardiac dysfunction induced by red blood cells in Type 2 diabetes. *Front Pharmacol.* 2019;10:861. <https://doi.org/10.3389/fphar.2019.00861>
PMid:31427970
- Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: Molecular insights and therapeutic strategies. *Cardiovasc Diabetol.* 2018;17(1):121. <https://doi.org/10.1186/s12933-018-0763-3>
PMid:30170601
- Hasan F, Hasan B. Antidiabetic medications and mortality reduction: A shift from surrogate to clinical endpoints. *Ther Adv Endocrinol Metab.* 2017;8(12):173-4. <https://doi.org/10.1177/2042018817737955>
PMid:29238516
- Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, Del Cañizo-Gómez FJ. Update on the treatment of Type 2 diabetes mellitus. *World J Diabetes.* 2016;7(17):354-95. <https://doi.org/10.4239/wjd.v7.i17.354>
PMid:27660695
- American Diabetes Association. 4. Lifestyle management: Standards of medical care in diabetes-2018. *Diabetes Care.* 2018;41 Suppl 1:S38-50. <https://doi.org/10.2337/dc18-s004>
PMid:29222375
- Polonsky WH, Henry RR. Poor medication adherence in Type 2 diabetes: Recognizing the scope of the problem and its key contributors. *Patient Prefer Adherence.* 2016;10:1299-307. <https://doi.org/10.2147/ppa.s106821>
PMid:27524885
- Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: A systematic review. *BMJ Open.* 2018;8(1):e016982. <https://doi.org/10.1136/bmjopen-2017-016982>
PMid:29358417
- Soewondo P, Ferrario A, Tahapary D. Challenges in diabetes management in Indonesia: A literature review. *Global Health.* 2013;9(1):63. <https://doi.org/10.1186/1744-8603-9-63>
PMid:24299164
- Rudianto A, Soewondo P, Waspadji S, Yunir E, Purnamasari D. The Indonesian society of endocrinology's summary article of diabetes mellitus national clinical practice guidelines. *JAFES.* 2011;26(1):17-9. <https://doi.org/10.15605/jafes.026.01.03>
- El-Beshbishy H, Bahashwan S. Hypoglycemic effect of basil (*Ocimum basilicum*) aqueous extract is mediated through inhibition of α -glucosidase and α -amylase activities: An *in vitro* study. *Toxicol Ind Health.* 2012;28(1):42-50. <https://doi.org/10.1177/0748233711403193>
PMid:21636683
- Ezeani C, Ezenyi I, Okoye T, Okoli C. *Ocimum basilicum* extract exhibits antidiabetic effects via inhibition of hepatic glucose mobilization and carbohydrate metabolizing enzymes. *J Intercult Ethnopharmacol.* 2017;6(1):22-8. <https://doi.org/10.5455/jice.20161229054825>
PMid:28163956

18. Widjaja SS, Rusdiana R, Savira M. Glucose lowering effect of basil leaves in diabetic rats. *Open Access Maced J Med Sci*. 2019;7(9):1415-7. <https://doi.org/10.3889/oamjms.2019.293>
PMid:31198445
19. Antora RA, Salleh RM. Antihyperglycemic effect of *Ocimum* plants: A short review. *Asian Pac J Trop Biomed*. 2017;7(8):755-9. <https://doi.org/10.1016/j.apjtb.2017.07.010>
20. Sari FA, Sandhika W, Yuliawati TH. Tulsi (*Ocimum sanctum*) leaf ethanol extract reduces inflammatory cell infiltration in aspirin-induced gastritis rats. *JKB*. 2020;31(1):49. <https://doi.org/10.21776/ub.jkb.2020.031.01.10>
21. Arozal W, Louisa M, Soetikno V. Selected Indonesian medicinal plants for the management of metabolic syndrome: Molecular basis and recent studies. *Front Cardiovasc Med*. 2020;7:82. <https://doi.org/10.3389/fcvm.2020.00082>
PMid:32435657
22. Pengpid S, Peltzer K. Use of traditional medicines and traditional practitioners by children in Indonesia: Findings from a national population survey in 2014-2015. *J Multidiscip Healthc*. 2019;12:291-8. <https://doi.org/10.2147/jmdh.s203343>
PMid:31114218
23. Vázquez-Fresno R, Rosana AR, Sajed T, Onokome-Okome T, Wishart NA, Wishart DS. Herbs and spices-biomarkers of intake based on human intervention studies-a systematic review. *Genes Nutr*. 2019;14(1):18. <https://doi.org/10.1186/s12263-019-0636-8>
PMid:31143299
24. Loha M, Mulu A, Abay SM, Ergete W, Geleta B. Acute and subacute toxicity of methanol extract of *Syzygium guineense* leaves on the histology of the liver and kidney and biochemical compositions of blood in rats. *Evid Based Complement Alternat Med*. 2019;2019:5702159. <https://doi.org/10.1155/2019/5702159>
PMid:30956682
25. Owu DU, Osim EE, Ebong PE. Serum liver enzymes profile of Wistar rats following chronic consumption of fresh or oxidized palm oil diets. *Acta Trop*. 1998;69(1):65-73. [https://doi.org/10.1016/s0001-706x\(97\)00115-0](https://doi.org/10.1016/s0001-706x(97)00115-0)
PMid:9588242
26. Thammitiyagodage MG, de Silva NR, Rathnayake C, Karunakaran R, Wgss K, Gunatillka MM, *et al*. Biochemical and histopathological changes in Wistar rats after consumption of boiled and un-boiled water from high and low disease prevalent areas for chronic kidney disease of unknown etiology (CKDu) in North Central Province (NCP) and its comparison with low disease prevalent Colombo, Sri Lanka. *BMC Nephrol*. 2020;21(1):38. <https://doi.org/10.1186/s12882-020-1693-3>
PMid:32005171
27. Awotunde OS, Adewoye SO, Dhanabal PS, Hawumba J. Subacute toxicity study of aqueous root extract of *Terminalia schimperiana* in male Wistar rats. *Toxicol Rep*. 2019;6:825-32. <https://doi.org/10.1016/j.toxrep.2019.07.006>
PMid:31463203
28. Kochhar A, Sharma N, Sachdeva R. Effect of supplementation of Tulsi (*Ocimum sanctum*) and Neem (*Azadirachta indica*) leaf powder on diabetic symptoms, anthropometric parameters and blood pressure of non-insulin dependent male diabetics. *Stud Ethno Med*. 2009;3(1):5-9. <https://doi.org/10.1080/09735070.2009.11886330>
29. Abilash S, Vijay Y, Deepthi T, Sri C, Vibha R, Swetha R, *et al*. Anti diabetic effect of ethanolic extract of leaves of *Ocimum sanctum* in alloxan induced diabetes in rats. *Int J Basic Clin Pharmacol*. 2013;2(5):613. <https://doi.org/10.5455/2319-2003.ijbcp20131018>
30. Hannan JM, Marenah L, Ali L, Rokeya B, Flatt PR, Abdel-Wahab YH. *Ocimum sanctum* leaf extracts stimulate insulin secretion from perfused pancreas, isolated islets and clonal pancreatic β -cells. *J Endocrinol*. 2006;189(1):127-36. <https://doi.org/10.1677/joe.1.06615>
PMid:16614387
31. Widjaja SS, Rusdiana R. Extract ethanol of poguntano in alloxan induced diabetic rats. *Bangladesh J Med Sci*. 2018;17(2):251-4. <https://doi.org/10.3329/bjms.v17i2.35879>
32. Huq A, Haque K, Khan AK. Clinical efficacy and safety of holy basil-based anti-diabetic tea. *J Sci Technol*. 2018;8(1-2):1-9.
33. Governa P, Baini G, Borgonetti V, Cettolin G, Giachetti D, Magnano A, *et al*. Phytotherapy in the management of diabetes: A review. *Molecules*. 2018 4;23(1):105. <https://doi.org/10.3390/molecules23010105>
PMid:29300317
34. Pattanayak P, Behera P, Das D, Panda S. *Ocimum sanctum* Linn. A reservoir plant for therapeutic applications: An overview. *Pharmacogn Rev*. 2010;4(7):95-105. <https://doi.org/10.4103/0973-7847.65323>
PMid:22228948
35. Lala V, Goyal A, Bansal P, Minter DA. Liver function test. In: *Stat Pearls*. Treasure Island, FL: Stat Pearls Publishing; 2020.
36. Ramachandran S, Rajasekaran A, Manisenthilkumar K. Investigation of hypoglycemic, hypolipidemic and antioxidant activities of aqueous extract of *Terminalia paniculata* bark in diabetic rats. *Asian Pac J Trop Biomed*. 2012;2(4):262-8. [https://doi.org/10.1016/s2221-1691\(12\)60020-3](https://doi.org/10.1016/s2221-1691(12)60020-3)
PMid:23569911